Colchicine as a Potential Treatment Choice for COVID-19 Patients in Developing Countries: COVID-19 and Colchicine
Authors:
- M.D.M.M.D.
- Jinseok KimJKJinseok Kim
Open Access
- 1 January 2022
- journal article
- letter
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 29 (1) , 56-57
Abstract
Byeongzu Ghang, M.D., Jinseok Kim, M.D.. J Rheum Dis 2022;29:56-7. https://doi.org/10.4078/jrd.2022.29.1.56Keywords
This publication has 11 references indexed in Scilit:
- Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trialThe Lancet Respiratory Medicine, 2021
- Six-month Follow-up Chest CT Findings after Severe COVID-19 PneumoniaRadiology, 2021
- Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic ReviewFrontiers in Immunology, 2021
- Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 AntibodiesFrontiers in Immunology, 2021
- Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trialRMD Open, 2021
- Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndromeAnnals of the Rheumatic Diseases, 2020
- Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019JAMA Network Open, 2020
- Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseasesNature Reviews Rheumatology, 2020
- Colchicine—Update on mechanisms of action and therapeutic usesSeminars in Arthritis and Rheumatism, 2015
- La colchicine: données récentes sur sa pharmacocinétique et sa pharmacologie cliniqueLa Revue de Médecine Interne, 1995